PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33798839-7 2021 Metformin exposure was also associated with decreased levels of the inflammatory cytokines TNFalpha, IL-1a, IL-1b and IL-6 in serum, placenta and omental tissue taken from pregnant women. Metformin 0-9 interleukin 6 Homo sapiens 118-122 34881181-7 2021 PD-L1 expression in ESCC cell lines was significantly inhibited by metformin via the IL-6/JAK2/STAT3 signaling pathway but was not correlated with the canonical AMPK pathway. Metformin 67-76 interleukin 6 Homo sapiens 85-89 34881181-0 2021 Metformin Downregulates PD-L1 Expression in Esophageal Squamous Cell Catrcinoma by Inhibiting IL-6 Signaling Pathway. Metformin 0-9 interleukin 6 Homo sapiens 94-98 34607979-6 2021 Accordingly, the p27 and p21 promoter activities were enhanced while Bcl-2 and IL-6 activities were significantly reduced by metformin treatment. Metformin 125-134 interleukin 6 Homo sapiens 79-83 34881181-10 2021 Conclusions: Metformin downregulated PD-L1 expression by blocking the IL-6/JAK2/STAT3 signaling pathway in ESCC, which enhanced the antitumor immune response. Metformin 13-22 interleukin 6 Homo sapiens 70-74 34572149-8 2021 In addition, metformin, a potential inhibitor of TLR4, also decreased expression of COX-2 and IL-6 induced by co-incubation with IL-26 and palmitate. Metformin 13-22 interleukin 6 Homo sapiens 94-98 35605453-10 2022 In addition, there was an increase in the serum levels of TNFalpha and IL-6 in type 2 diabetic patients and this was reversed with metformin treatment. Metformin 131-140 interleukin 6 Homo sapiens 71-75 34284806-12 2021 Metformin promoted SFRP5 and decreased leptin, IL-6 and TNFalpha secretion in PCOS women with metabolic abnormality in a time dependent manner and with improved ovulation rate and pregnancy rate. Metformin 0-9 interleukin 6 Homo sapiens 47-51 34115964-3 2021 We show that metformin inhibited NLRP3 inflammasome activation and interleukin (IL)-1beta production in cultured and alveolar macrophages along with inflammasome-independent IL-6 secretion, thus attenuating lipopolysaccharide (LPS)- and SARS-CoV-2-induced ARDS. Metformin 13-22 interleukin 6 Homo sapiens 174-178 34238029-0 2021 Metformin Antagonizes Ovarian Cancer Cells Malignancy Through MSLN Mediated IL-6/STAT3 Signaling. Metformin 0-9 interleukin 6 Homo sapiens 76-80 34238029-8 2021 On mechanism, metformin treatment remarkably reduced mesothelin (MSLN) expression, downregulated IL-6/STAT3 signaling activity, subsequently resulted in VEGF and TGFbeta1 expression. Metformin 14-23 interleukin 6 Homo sapiens 97-101 34238029-10 2021 CONCLUSIONS: Collectively, our findings suggested that metformin exerts anticancer effects by suppressing ovarian cancer cell malignancy, which attributed to MSLN inhibition mediated IL6/STAT3 signaling and VEGF and TGFbeta1 downregulation. Metformin 55-64 interleukin 6 Homo sapiens 183-186 33017649-8 2021 Cumulative evidence from these RCTs supported the blood glucose lowering effects of metformin, in addition to promoting weight loss, ameliorating insulin resistance, and reducing pro-inflammatory markers such as interleukin-6 and tumor necrosis factor-alpha in patients with metabolic syndrome. Metformin 84-93 interleukin 6 Homo sapiens 212-225 35620570-3 2022 Results: The empagliflozin-metformin combination increased levels of the antioxidants (TAS, SOD, and GPx up to 1.1-fold; P < 0.01), decreased the levels of prooxidants (AOPP and isoprostanes up to 1.2-fold, P < 0.01; AGE up to 1.5-fold, P < 0.01), and decreased inflammatory parameters (up to 1.5-fold, CRP P < 0.01; IL-6 P < 0.001). Metformin 27-36 interleukin 6 Homo sapiens 317-321 33580540-2 2021 Metformin is known to decrease interleukin-6 (IL-6) and tumor-necrosis alpha (TNFalpha), which appear to contribute to morbidity in COVID-19. Metformin 0-9 interleukin 6 Homo sapiens 31-44 33580540-2 2021 Metformin is known to decrease interleukin-6 (IL-6) and tumor-necrosis alpha (TNFalpha), which appear to contribute to morbidity in COVID-19. Metformin 0-9 interleukin 6 Homo sapiens 46-50 32674107-5 2021 METHODS: In MH7A cells, cell proliferation and the IL-6-mediated signaling pathway following administration of LMT-28 and metformin combination was analyzed through MTT assay and Western blotting. Metformin 122-131 interleukin 6 Homo sapiens 51-55 32674107-8 2021 RESULTS: Combination treatment with LMT-28 and metformin diminished proliferation of MH7A cells and IL-6-mediated gp130, STAT3, and ERK signaling more than in individual treatments. Metformin 47-56 interleukin 6 Homo sapiens 100-104 32674107-12 2021 CONCLUSION: Combination treatment with LMT-28 and metformin significantly ameliorates arthritic symptoms in CIA by suppressing Th17 differentiation and IL-6 signaling. Metformin 50-59 interleukin 6 Homo sapiens 152-156 33116117-10 2020 Furthermore, results showed that the stemness inhibition by metformin was associated with blockade of the IL6-stat3 axis. Metformin 60-69 interleukin 6 Homo sapiens 106-109 32859615-8 2020 Compared with control, exercise and metformin reduced sTNF-alphaR2: -13.1% (95% CI: -22.9, -1.0) and IL-6: -38.7% (95% CI: -52.3, -18.9); but did not change hs-CRP: -20.5% (95% CI: -44.0, 12.7). Metformin 36-45 interleukin 6 Homo sapiens 101-105 33116117-11 2020 Survival analysis demonstrated that overexpression of IL6 and stemness markers was associated with poor survival in HNSCC patients, indicating that including metformin to target these proteins might improve patient prognosis. Metformin 158-167 interleukin 6 Homo sapiens 54-57 32967076-5 2020 Patients treated with metformin showed decreased levels of all analyzed serum pro-inflammatory markers (TNFalpha, IL6, IL1beta and MCP1) and a downwards trend in IL18 levels associated with a lower production of oxidative stress markers in leukocytes (mitochondrial ROS and myeloperoxidase (MPO)). Metformin 22-31 interleukin 6 Homo sapiens 114-117 33081905-12 2020 The possible mechanism is that metformin could inhibit cytokine storm via suppressing interleukin-6 (IL-6) signaling, prevent the process of lung fibrosis, suppress endocytosis, thereby elevating angiotensin converting enzyme 2 (ACE2) expression. Metformin 31-40 interleukin 6 Homo sapiens 86-99 33081905-12 2020 The possible mechanism is that metformin could inhibit cytokine storm via suppressing interleukin-6 (IL-6) signaling, prevent the process of lung fibrosis, suppress endocytosis, thereby elevating angiotensin converting enzyme 2 (ACE2) expression. Metformin 31-40 interleukin 6 Homo sapiens 101-105 31840936-12 2020 Metformin or AICAR presence decreased spontaneous production of IL-6, IL-8 and MCP-1 in RA synovial explants and SFCs (n=5-7). Metformin 0-9 interleukin 6 Homo sapiens 64-68 31346700-4 2019 By acting on IL-6 expression, metformin might have a positive impact on the main molecular pathways strictly connected with pathogenesis and biological features of ovarian cancer. Metformin 30-39 interleukin 6 Homo sapiens 13-17 32463794-2 2020 Metformin is capable of suppressing one of the molecular triggers of the proinflammatory and prothrombotic processes of urban PM air pollution, namely the mitochondrial ROS/Ca2+ release-activated Ca2+ channels (CRAC)/IL-6 cascade. Metformin 0-9 interleukin 6 Homo sapiens 217-221 32463794-3 2020 Given the linkage between mitochondrial functionality, ion channels, and inflamm-aging, the ability of metformin to target mitochondrial electron transport and prevent ROS/CRAC-mediated IL-6 release might illuminate new therapeutic avenues to quell the raging of the cytokine and thrombotic-like storms that are the leading causes of COVID-19 morbidity and mortality in older people. Metformin 103-112 interleukin 6 Homo sapiens 186-190 32258099-12 2020 Further study revealed that metformin may attenuate the phosphorylation of the Stat3 and the Bcl-2 expression, which was restored by IL-6 partly in EC109 cells but not HEECs. Metformin 28-37 interleukin 6 Homo sapiens 133-137 32769032-8 2020 RESULTS: Metformin showed maximum percent declined from baseline to three months therapy in levels of fructosamine, beta-amyloid, sRAGE, inflammatory cytokines (IL-6, TNF-alpha) and percent increment in esRAGE and antioxidants levels. Metformin 9-18 interleukin 6 Homo sapiens 161-165 30988378-0 2019 Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells. Metformin 0-9 interleukin 6 Homo sapiens 19-23 32518807-9 2020 After metformin treatment, expression of interleukin 6 (IL-6), TNF-alpha, and IL-1beta were significantly downregulated in RA-FLSs; however, increased expression of p-AMPK-alpha1, protein kinase A (PKA)-alpha1, and HAPLN1 (hyaluronan and proteoglycan link protein 1) was observed. Metformin 6-15 interleukin 6 Homo sapiens 41-54 32518807-9 2020 After metformin treatment, expression of interleukin 6 (IL-6), TNF-alpha, and IL-1beta were significantly downregulated in RA-FLSs; however, increased expression of p-AMPK-alpha1, protein kinase A (PKA)-alpha1, and HAPLN1 (hyaluronan and proteoglycan link protein 1) was observed. Metformin 6-15 interleukin 6 Homo sapiens 56-60 32312819-7 2020 Furthermore, glutamine deprivation, as well as the antimetabolic drugs 2-deoxyglucose and metformin, also promoted the release of IL-6 and IL-8. Metformin 90-99 interleukin 6 Homo sapiens 130-134 31683341-0 2019 Treatment with Metformin and Combination of Metformin Plus Pioglitazone on Serum Levels of IL-6 and IL-8 in Polycystic Ovary Syndrome: A Randomized Clinical Trial. Metformin 44-53 interleukin 6 Homo sapiens 91-95 31683341-14 2019 Combination of metformin and pioglitazone therapy was more effective as compared to metformin alone in reducing the levels of IL-6 and IL-8 as well as insulin resistance in PCOS. Metformin 15-24 interleukin 6 Homo sapiens 126-130 31683341-14 2019 Combination of metformin and pioglitazone therapy was more effective as compared to metformin alone in reducing the levels of IL-6 and IL-8 as well as insulin resistance in PCOS. Metformin 84-93 interleukin 6 Homo sapiens 126-130 31154939-15 2019 Metformin treatment decreased inflammation, IL-6 levels, STAT3 activation, and human PA smooth muscle cell proliferation. Metformin 0-9 interleukin 6 Homo sapiens 44-48 31442575-7 2019 Metformin and Liraglutide were shown to elicit significantly greater release of TNFa, IL-6, and GM-CSF, while Sitagliptin had a lesser effect on pro-inflammatory cytokine production. Metformin 0-9 interleukin 6 Homo sapiens 86-90 31154939-16 2019 In vivo, in the supracoronary aortic banding+MetS animals, reducing IL-6, either by anti-IL-6 antibody or metformin treatment, reversed pulmonary vascular remodeling and improve PH due to LHD. Metformin 106-115 interleukin 6 Homo sapiens 68-72 30959417-8 2019 Treatment of insulin resistant cells with SF or metformin alone decreased levels of reactive oxygen species (ROS), malondialdehyde (MDA), tumor necrosis factor (TNF-alpha) and interleukin-6 (IL-6); whereas antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT) activity, as well as total antioxidant capacity (T-AOC) ability increased. Metformin 48-57 interleukin 6 Homo sapiens 176-189 31337349-14 2019 CONCLUSION: These results suggest that MTF inhibits IL-6-induced EMT, cell proliferation, and migration of primary breast cancer cells by preventing the activation of STAT3 and NF-kappaB. Metformin 39-42 interleukin 6 Homo sapiens 52-56 30959417-8 2019 Treatment of insulin resistant cells with SF or metformin alone decreased levels of reactive oxygen species (ROS), malondialdehyde (MDA), tumor necrosis factor (TNF-alpha) and interleukin-6 (IL-6); whereas antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT) activity, as well as total antioxidant capacity (T-AOC) ability increased. Metformin 48-57 interleukin 6 Homo sapiens 191-195 30334569-5 2019 Metformin also significantly ( p < 0.05) inhibited TAA-induced HIF-1alpha, mTOR, the profibrogenic biomarker alpha-smooth muscle actin, tissue inhibitor of metalloproteinases-1, tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), alanine aminotransferase (ALT) and aspartate aminotransferase in harvested liver homogenates and blood samples. Metformin 0-9 interleukin 6 Homo sapiens 219-232 30334569-5 2019 Metformin also significantly ( p < 0.05) inhibited TAA-induced HIF-1alpha, mTOR, the profibrogenic biomarker alpha-smooth muscle actin, tissue inhibitor of metalloproteinases-1, tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), alanine aminotransferase (ALT) and aspartate aminotransferase in harvested liver homogenates and blood samples. Metformin 0-9 interleukin 6 Homo sapiens 234-238 30318339-3 2019 Treatment of mice with metformin or exposure of murine or human alveolar macrophages to metformin prevented the particulate matter-induced generation of complex III mitochondrial reactive oxygen species, which were necessary for the opening of calcium release-activated channels (CRAC) and release of IL-6. Metformin 23-32 interleukin 6 Homo sapiens 301-305 30628691-10 2019 Furthermore, it was confirmed that metformin suppressed the LPS-induced secretion of TNF-alpha, IL-6, ICAM-1 and VCAM-1. Metformin 35-44 interleukin 6 Homo sapiens 96-100 30318339-3 2019 Treatment of mice with metformin or exposure of murine or human alveolar macrophages to metformin prevented the particulate matter-induced generation of complex III mitochondrial reactive oxygen species, which were necessary for the opening of calcium release-activated channels (CRAC) and release of IL-6. Metformin 88-97 interleukin 6 Homo sapiens 301-305 29589999-11 2018 The IL-1beta-induced hyaluronan production and mRNA expression of IL-6, cyclooxygenase-2, and intercellular adhesion molecule-1 were also significantly suppressed after metformin or phenformin co-treatment. Metformin 169-178 interleukin 6 Homo sapiens 66-70 30308035-0 2018 Anti-metastatic effect of metformin via repression of interleukin 6-induced epithelial-mesenchymal transition in human colon cancer cells. Metformin 26-35 interleukin 6 Homo sapiens 54-67 30308035-7 2018 Furthermore, pathway analysis revealed that the metformin-predicted group was characterized by decreased interleukin (IL)-6 pathway signaling, epithelial-mesenchymal transition, and colon cancer metastatic signaling. Metformin 48-57 interleukin 6 Homo sapiens 105-123 30308035-10 2018 These findings suggest that blockade of IL-6-induced epithelial-mesenchymal transition is an antitumor mechanism of metformin. Metformin 116-125 interleukin 6 Homo sapiens 40-44 29540537-7 2018 Expression of active form of AMP-activated protein kinase was reduced in inflammatory bowel disease patients and treatment of mucosal cells of such patients with metformin enhanced AMP-activated protein kinase activation and reduced p38 MAP kinase activation, thereby inhibiting interleukin-6 expression. Metformin 162-171 interleukin 6 Homo sapiens 279-292 29545331-7 2018 For the first time, we found that the tumor stroma of patients with routine metformin administration exhibited lower IL6 expression. Metformin 76-85 interleukin 6 Homo sapiens 117-120 29545331-10 2018 Mechanistically, we found that metformin inhibited IL6 secretion via suppressing NFkappaB signaling, an upstream controller of stromal inflammation. Metformin 31-40 interleukin 6 Homo sapiens 51-54 30520054-4 2019 Our results demonstrated that metformin significantly decreased the mRNA and protein levels of tumour necrosis factor-alpha (TNFalpha), interleukin (IL)-6, IL-8, and IL-1beta induced by TNFalpha. Metformin 30-39 interleukin 6 Homo sapiens 136-154 30334082-10 2019 A novel association appeared for change in IL-6 in the metformin group (1.09 [1.021, 1.173]) and for baseline leptin in the lifestyle groups (1.31 [1.06, 1.63]). Metformin 55-64 interleukin 6 Homo sapiens 43-47 28953677-0 2017 Effects of metformin treatment on serum levels of C-reactive protein and interleukin-6 in women with polycystic ovary syndrome: a meta-analysis: A PRISMA-compliant article. Metformin 11-20 interleukin 6 Homo sapiens 73-86 29148173-6 2018 We found that metformin ameliorated the induction of colitis and reduced the levels of pro-inflammatory cytokines IL-6, TNF-a and IL-1beta. Metformin 14-23 interleukin 6 Homo sapiens 114-118 28953677-1 2017 BACKGROUND: Metformin is effective for the treatment of polycystic ovary syndrome (PCOS), but conflicting results regarding its impact on serum levels of C-reactive protein (CRP) and interleukin-6 (IL-6) in women with PCOS have been reported. Metformin 12-21 interleukin 6 Homo sapiens 183-196 28953677-1 2017 BACKGROUND: Metformin is effective for the treatment of polycystic ovary syndrome (PCOS), but conflicting results regarding its impact on serum levels of C-reactive protein (CRP) and interleukin-6 (IL-6) in women with PCOS have been reported. Metformin 12-21 interleukin 6 Homo sapiens 198-202 28953677-13 2017 In addition, we noticed that metformin treatment could decrease BMI in the CRP and IL-6 related studies (SMD = -0.45, 95% CI: -0.68 to -0.23; SMD = -0.44, 95% CI: -0.73 to -0.16). Metformin 29-38 interleukin 6 Homo sapiens 83-87 26320144-10 2015 In addition, metformin reduced glucose, follicle-stimulating hormone, IL6 and TNFalpha levels and increased dehydroepiandrosterone sulfate levels. Metformin 13-22 interleukin 6 Homo sapiens 70-73 27904436-3 2016 In the present study, we determined the effects of metformin on the levels of pro-inflammatory cytokines (i.e., IL-6, TNF-alpha, and MCP-1) and anti-inflammatory mediator IL-10 in blood and urine of patients with type 2 diabetes. Metformin 51-60 interleukin 6 Homo sapiens 112-116 27904436-6 2016 RESULTS: We found that metformin reduced the levels of IL-6 in blood and MCP-1 in urine, but increased IL-10 levels in blood of patients with type 2 diabetes. Metformin 23-32 interleukin 6 Homo sapiens 55-59 27904436-8 2016 Furthermore, compared to individual drug treatment, metformin significantly reduced the levels of serum IL-6 and TNF-alpha, as well as urine MCP-1. Metformin 52-61 interleukin 6 Homo sapiens 104-108 26305116-9 2016 Metformin can exert an anti-inflammatory effect by direct inhibition of IL-6, TNF-alpha, and VEGF. Metformin 0-9 interleukin 6 Homo sapiens 72-76 27418629-3 2016 METHODS AND RESULTS: In primary hepatocytes from healthy animals, metformin and the IKKbeta (inhibitor of kappa B kinase) inhibitor BI605906 both inhibited tumor necrosis factor-alpha-dependent IkappaB degradation and expression of proinflammatory mediators interleukin-6, interleukin-1beta, and CXCL1/2 (C-X-C motif ligand 1/2). Metformin 66-75 interleukin 6 Homo sapiens 258-271 26963617-12 2016 In the SHR-CRP transgenic strain, we found that metformin treatment decreased circulating levels of inflammatory response marker IL-6, TNFalpha and MCP-1 while levels of human CRP remained unchanged. Metformin 48-57 interleukin 6 Homo sapiens 129-133 26896068-9 2016 Moreover, metformin enhanced the anti-inflammatory effect of 5-ASA by decreasing the gene expression of IL-1beta, IL-6, COX-2 and TNF-alpha and its receptors; TNF-R1 and TNF-R2. Metformin 10-19 interleukin 6 Homo sapiens 114-118 26120598-6 2015 Further investigation into the effects of metformin suggest that the drug directly activates AMPK and dose-dependently suppressed the release of TNF-alpha, IL-6, and MCP-1 by macrophages while enhancing the release of IL-10 in vitro. Metformin 42-51 interleukin 6 Homo sapiens 156-160 26081514-8 2015 In metformin-treated cells, the expressions of Arg1 (P = 0.009), IL-10 (P = 0.015) and IL-4 (P = 0.001) mRNA increased while the expressions of IL-1beta (P = 0.001) and IL-6 (P = 0.032) mRNA decreased. Metformin 3-12 interleukin 6 Homo sapiens 169-173 26141671-6 2015 In addition, treatment with metformin significantly reduced the expression of IL-6 and TNF-alpha at the messenger RNA level and attenuated nuclear factor kappa B (NF-kappaB) DNA binding activity in MNCs. Metformin 28-37 interleukin 6 Homo sapiens 78-82 23659985-12 2013 Finally, metformin dose-dependently reduced TNF-alpha-induced IL-6 and IkappaBalpha levels in cultured placental JAR cells. Metformin 9-18 interleukin 6 Homo sapiens 62-66 24644001-0 2014 Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Metformin 0-9 interleukin 6 Homo sapiens 107-111 24644001-4 2014 This study aims to investigate the effect of metformin on sensitizing EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Metformin 45-54 interleukin 6 Homo sapiens 156-160 24644001-7 2014 Metformin reversed EMT and decreased IL-6 signaling activation in TKI-resistant cells, while adding IL-6 to those cells bypassed the anti-TKI-resistance effect of metformin. Metformin 0-9 interleukin 6 Homo sapiens 37-41 25096410-0 2014 Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review. Metformin 10-19 interleukin 6 Homo sapiens 29-42 25096410-5 2014 Studies were selected that evaluated the effect of metformin on IL-6 levels in PCOS patients. Metformin 51-60 interleukin 6 Homo sapiens 64-68 25096410-8 2014 Of these, one study reported a significant decrease in IL-6 levels after metformin treatment in women with PCOS. Metformin 73-82 interleukin 6 Homo sapiens 55-59 25096410-11 2014 CONCLUSIONS: Serum IL-6 levels of PCOS patients may be influenced by metformin. Metformin 69-78 interleukin 6 Homo sapiens 19-23 25096410-13 2014 However, further investigations with larger samples are needed to better understand the effects of metformin on IL-6 levels and chronic inflammation in PCOS. Metformin 99-108 interleukin 6 Homo sapiens 112-116 24644001-7 2014 Metformin reversed EMT and decreased IL-6 signaling activation in TKI-resistant cells, while adding IL-6 to those cells bypassed the anti-TKI-resistance effect of metformin. Metformin 163-172 interleukin 6 Homo sapiens 100-104 24644001-8 2014 Furthermore, overexpression or addition of IL-6 to TKI-sensitive cells induced TKI resistance, which could be overcome by metformin. Metformin 122-131 interleukin 6 Homo sapiens 43-47 24644001-9 2014 Finally, metformin-based combinatorial therapy effectively blocked tumor growth in xenografts with TKI-resistant cancer cells, which was associated with decreased IL-6 secretion and expression, EMT reversal, and decreased IL-6-signaling activation in vivo. Metformin 9-18 interleukin 6 Homo sapiens 163-167 24644001-9 2014 Finally, metformin-based combinatorial therapy effectively blocked tumor growth in xenografts with TKI-resistant cancer cells, which was associated with decreased IL-6 secretion and expression, EMT reversal, and decreased IL-6-signaling activation in vivo. Metformin 9-18 interleukin 6 Homo sapiens 222-226 23526220-8 2013 Metformin also inhibited cisplatin-induced ROS production and autocrine IL-6 secretion in AS2 cells. Metformin 0-9 interleukin 6 Homo sapiens 72-76 23526220-11 2013 This is the first study to demonstrate that metformin suppresses STAT3 activation via LKB1-AMPK-mTOR-independent but ROS-related and autocrine IL-6 production-related pathways. Metformin 44-53 interleukin 6 Homo sapiens 143-147 23611575-2 2013 The administration of metformin reduced pain intensity from 9/10 to 3/10 and favorably affected the profile of inflammatory cytokines (i.e., TNF a, IL-1beta, IL-6, and IL-10), adipokines (i.e., adiponectin, leptin, and resistin), and beta-endorphin. Metformin 22-31 interleukin 6 Homo sapiens 158-162 21774820-9 2011 Induction of IL-6 mRNA by LPS was reduced by metformin (p < 0.01), while the LPS-induced mRNA expression of the naturally occurring anti-inflammatory cytokine interleukin 1 receptor antagonist was increased (p < 0.01). Metformin 45-54 interleukin 6 Homo sapiens 13-17 24399727-6 2013 RESULTS: Metformin treatment reduced plasma C-reactive protein levels and monocyte release of tumor necrosis factor-alpha and interleukin-6, as well as tended to reduce monocyte release of interleukin-1beta and monocyte chemoattractant protein-1, which was accompanied by an improvement in insulin sensitivity. Metformin 9-18 interleukin 6 Homo sapiens 126-139 21801267-7 2011 Treatment with metformin significantly reduced IL-6, especially in PCOS patients with IRS-2 homozygous Asp variant. Metformin 15-24 interleukin 6 Homo sapiens 47-51 22841520-5 2013 RESULTS: Compared to placebo, metformin reduced monocyte release of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, monocyte chemoattractant protein-1 and interleukin-8, as well as decreased plasma C-reactive protein levels, which were accompanied by an improvement in insulin sensitivity. Metformin 30-39 interleukin 6 Homo sapiens 116-129 23091851-8 2012 The CHD and MS patients who carried the Pro allele showed a significant metformin-induced reduction in weight, waist circumference, body mass index, and concentrations of TC, C-peptide, and cytokines, such IL-1beta, IL-6, IL-8, and TNF-alpha. Metformin 72-81 interleukin 6 Homo sapiens 216-220 21424914-9 2011 In the metformin group, body mass index, PPG, HbA1c, IL-6, ICAM-1, and TNF-alpha levels were significantly decreased after 12 weeks compared with the basal levels. Metformin 7-16 interleukin 6 Homo sapiens 53-57 21031343-12 2011 CONCLUSIONS: Both rosiglitazone/metformin combination therapy and metformin monotherapy decreased serum vaspin levels through glucose and insulin sensitivity regulation, while they exerted differential effects on adiponectin, IL-6 and other cardiovascular risk factors in drug-naive patients with T2DM. Metformin 66-75 interleukin 6 Homo sapiens 226-230 20956498-10 2011 Furthermore, metformin decreased IL-6 and MCP-1 gene expression in comparison with differentiated adipocytes. Metformin 13-22 interleukin 6 Homo sapiens 33-37 20730705-0 2010 Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin-6 concentrations. Metformin 51-60 interleukin 6 Homo sapiens 131-144 20652679-2 2010 METHODS: IL-6-stimulated expression of the genes for acute-phase response markers serum amyloid A (SAA1, SAA2) and haptoglobin (HP) in the human hepatocarcinoma cell line HepG2 were quantified after modulation of AMPK activity by pharmacological agonists (5-amino-4-imidazole-carboxamideriboside [AICAR], metformin) or by using small interfering (si) RNA transfection. Metformin 305-314 interleukin 6 Homo sapiens 9-13 20652679-4 2010 RESULTS: AICAR and metformin markedly blunt the IL-6-stimulated expression of SAA cluster genes as well as of haptoglobin in a dose-dependent manner. Metformin 19-28 interleukin 6 Homo sapiens 48-52 21954641-1 2011 The use of metformin during the first month of treatment of patients with coronary artery disease and diabetes type 2 led to the decrease of insulin resistance and reduced activity of systemic inflammation (significant decrease in the concentrations of IL-1, IL-6, IL-8 and TNF-alpha). Metformin 11-20 interleukin 6 Homo sapiens 259-263 20730705-2 2010 We aimed to study if the changes observed in the insulin sensitivity of PCOS patients during treatment with oral contraceptives or metformin associate changes in the serum inflammatory markers interleukin-6 (IL-6) and interleukin-18 (IL-18). Metformin 131-140 interleukin 6 Homo sapiens 193-206 20730705-2 2010 We aimed to study if the changes observed in the insulin sensitivity of PCOS patients during treatment with oral contraceptives or metformin associate changes in the serum inflammatory markers interleukin-6 (IL-6) and interleukin-18 (IL-18). Metformin 131-140 interleukin 6 Homo sapiens 208-212 20730705-6 2010 PCOS women treated with metformin showed a decrease in IL-6 levels throughout the study compared with women treated with Diane (35) Diario (-33% change vs. +23% change, F=3.709, p=0.048; intention-to-treat analysis: F=5.569, p=0.011). Metformin 24-33 interleukin 6 Homo sapiens 55-59 20730705-8 2010 The decrease in IL-6 levels in women receiving metformin occurred in parallel to the increase in the insulin sensitivity index (r=-0.579, p=0.048; intention-to-treat analysis, r=-0.687, p=0.001). Metformin 47-56 interleukin 6 Homo sapiens 16-20 20730705-9 2010 In conclusion, serum IL-6 levels decreased during treatment with metformin in parallel to amelioration of insulin resistance, whereas oral contraceptives slightly increased circulating IL-6 levels without changing insulin sensitivity. Metformin 65-74 interleukin 6 Homo sapiens 21-25 18597869-0 2009 Metformin inhibits TNF-alpha-induced IkappaB kinase phosphorylation, IkappaB-alpha degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation. Metformin 0-9 interleukin 6 Homo sapiens 99-103 19494326-3 2009 We provide evidence that metformin attenuates the induction of EAE by restricting the infiltration of mononuclear cells into the CNS, down-regulating the expression of proinflammatory cytokines (IFN-gamma, TNF-alpha, IL-6, IL-17, and inducible NO synthase (iNOS)), cell adhesion molecules, matrix metalloproteinase 9, and chemokine (RANTES). Metformin 25-34 interleukin 6 Homo sapiens 217-221 18597869-7 2009 Pre-treatment with metformin (100-1000 micromol/L) also inhibited TNF-alpha-induced IL-6 production, phosphorylation of IkappaB kinase (IKK) alpha/beta and IkappaB-alpha degradation. Metformin 19-28 interleukin 6 Homo sapiens 84-88 18597869-10 2009 Transfection of siRNA against alpha1-AMPK eradicated the inhibitory effects of metformin on TNF-alpha-induced IL-6, implying the essential role of AMPK. Metformin 79-88 interleukin 6 Homo sapiens 110-114 18597869-11 2009 CONCLUSIONS: Metformin had anti-inflammatory effects on endothelial cells and inhibited TNF-alpha-induced IKKalpha/beta phosphorylation, IkappaB-alpha degradation and IL-6 production in HUVEC. Metformin 13-22 interleukin 6 Homo sapiens 167-171 18820825-6 2009 Treatment with pioglitazone, associated with metformin, showed a reduction of IL-6 monocyte production after their in vitro activation with LPS. Metformin 45-54 interleukin 6 Homo sapiens 78-82 19188739-4 2009 After 6 weeks of metformin therapy (n = 37) there was a significant reduction in BMI (p < 0.001), waist (p < 0.001) and CRP (p < 0.01), while at 6 months there was not only a significant reduction in BMI and waist but also in HOMA-R (p = 0.01) and IL-6 levels (p < 0.01) with no further reduction of CRP. Metformin 17-26 interleukin 6 Homo sapiens 257-261 19188739-7 2009 Metformin-associated reduction of CRP levels prior to any significant changes in insulin resistance or IL-6 perhaps involves different mechanisms of action. Metformin 0-9 interleukin 6 Homo sapiens 103-107 18082089-7 2007 Pharmacological treatment with either rosuvastatin or metformin lead to reductions in IL-6, TNFalpha, GSH and GPx levels and an increase in the SOD level, and there were significant interactions between the two treatment groups for these variables. Metformin 54-63 interleukin 6 Homo sapiens 86-90 16385087-4 2006 METHODS AND RESULTS: Metformin dose-dependently inhibited IL-1beta-induced release of the pro-inflammatory cytokines IL-6 and IL-8 in ECs, SMCs, and Mphis. Metformin 21-30 interleukin 6 Homo sapiens 117-121